24/7 Market News Snapshot 05 February, 2025 – Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV)

February 5, 2025

DENVER, Colo., 05 February, 2025 (247marketnews.com) – (NASDAQ:ACRV) are discussed in this article.
Acrivon Therapeutics, Inc. (ACRV) has experienced a notable surge in stock performance, with shares opening at $5.83 and reaching $6.966, marking a substantial increase of approximately 17.87%. Following a previous closing price of $5.91, this upward trend is accompanied by a significant trading volume of 550.91K, indicating strong investor interest and suggesting a potential breakout from resistance levels. The evident bullish sentiment may provide traders with opportunities within the biotech sector as technical indicators point towards further gains.

In a groundbreaking advancement for the company, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to Acrivon’s ACR-368 OncoSignature assay. This state-of-the-art multiplex immunofluorescence assay is tailored to identify patients with endometrial cancer likely to benefit from ACR-368 therapy, reinforcing Acrivon’s commitment to precision medicine in oncology.

Recent clinical data presented at the ESMO 2024 conference revealed an impressive overall response rate of 62.5% among biomarker-positive patients selected via the OncoSignature process. This outcome demonstrates a statistically significant difference from biomarker-negative groups (p-value = 0.009), marking a pivotal advancement in treating high-grade, locally advanced, or metastatic endometrial cancer, which affects around 30,000 new patients annually.

Peter Blume-Jensen, M.D., Ph.D., CEO and founder of Acrivon Therapeutics, expressed enthusiasm over this FDA designation, emphasizing the validation it brings to the ACR-368 OncoSignature assay and the Acrivon Predictive Precision Proteomics (AP3) platform. He noted that ongoing Phase 2b trials for ACR-368 could significantly impact patients battling endometrial cancer and beyond. The AI-driven AP3 platform aims to enhance drug design and improve prediction of clinical outcomes as Acrivon progresses further in biomarker development and precision oncology.

Related news for (ACRV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.